Day One Biopharmaceuticals (NASDAQ:DAWN) Posts Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) released its quarterly earnings data on Thursday. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09), MarketWatch Earnings reports.

Shares of DAWN stock traded up $0.70 during trading hours on Friday, reaching $7.65. The company had a trading volume of 461,834 shares, compared to its average volume of 218,898. The stock’s fifty day simple moving average is $10.14 and its 200 day simple moving average is $14.57. Day One Biopharmaceuticals has a twelve month low of $6.53 and a twelve month high of $28.70.

Separately, Zacks Investment Research upgraded Day One Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $34.25.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada bought a new position in Day One Biopharmaceuticals during the third quarter worth about $33,000. Morgan Stanley bought a new position in Day One Biopharmaceuticals during the second quarter worth about $54,000. Citigroup Inc. grew its holdings in Day One Biopharmaceuticals by 266.1% during the fourth quarter. Citigroup Inc. now owns 4,682 shares of the company’s stock worth $79,000 after purchasing an additional 3,403 shares during the period. Bank of America Corp DE grew its holdings in Day One Biopharmaceuticals by 1,074.6% during the fourth quarter. Bank of America Corp DE now owns 5,685 shares of the company’s stock worth $96,000 after purchasing an additional 5,201 shares during the period. Finally, California State Teachers Retirement System bought a new position in Day One Biopharmaceuticals during the third quarter worth about $141,000. Institutional investors own 79.02% of the company’s stock.

About Day One Biopharmaceuticals (Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Stories

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.